Sildenafil: Nursing Drug Guide, Nitrate Interaction & NCLEX Review
Sildenafil can improve erectile dysfunction symptoms and pulmonary arterial hypertension hemodynamics, but the nursing never-miss danger is coadministration with nitrates or riociguat, which can trigger abrupt life-threatening hypotension with collapse.
The most dangerous sildenafil failure is administering it while organic nitrates are present or riociguat is active. Combined cGMP pathway effects can cause profound hypotension, syncope, and organ hypoperfusion within minutes, so interaction screening must occur before every dose and order verification.
📋 Contents
⚡ Quick facts
💡 Key takeaway
Before giving sildenafil, confirm no nitrate products and no riociguat on active medication list, complete interaction-focused reconciliation, and verify the intended indication dose schedule to prevent avoidable hypotension events.
Most common brand names
Sildenafil appears as Viagra for erectile dysfunction and as pulmonary arterial hypertension products such as Revatio formulations. Confirm indication-specific product, concentration, and schedule before administration to avoid wrong-dose errors.
| Product | Typical use | Nursing verification |
|---|---|---|
| Viagra tablets | Erectile dysfunction, on-demand use | Verify PRN timing and once-daily maximum frequency |
| PAH sildenafil tablets | Pulmonary arterial hypertension maintenance | Confirm routine TID schedule spaced 4 to 6 hours apart |
| PAH sildenafil oral suspension | PAH when liquid dosing is needed | Measure carefully and keep dose interval consistency |
On a small screen, swipe or scroll sideways to see the full table.
Why we give it — Indications
Sildenafil is indicated for erectile dysfunction symptom relief and for pulmonary arterial hypertension to improve exercise ability and delay clinical worsening. Review symptom context, comorbidities such as heart failure, and current cardioactive therapies before each dose decision, especially when patients also carry a history of angina.
| Indication | Label-based summary |
|---|---|
| Erectile dysfunction | Oral PRN dosing to improve erectile response when sexually stimulated |
| Pulmonary arterial hypertension | Scheduled oral dosing to support pulmonary hemodynamics and functional capacity |
| Not for acute chest ischemia | Do not use sildenafil as rescue treatment for active chest pain episodes |
On a small screen, swipe or scroll sideways to see the full table.
How it works
Sildenafil inhibits phosphodiesterase-5, preserving cGMP-mediated smooth-muscle relaxation in penile and pulmonary vascular tissue. This same pathway explains why coadministration with nitroglycerin or riociguat can precipitate dangerous blood pressure collapse.
| Effect | Clinical impact | Nursing implication |
|---|---|---|
| PDE5 inhibition | Higher cGMP activity and vasodilation | Expect BP-lowering potential, especially with interacting drugs |
| Pulmonary vascular relaxation | Lower pulmonary vascular resistance in PAH | Track dyspnea tolerance and hemodynamic stability over time |
| Penile tissue smooth-muscle relaxation | Improved erectile response | Use indication-specific counseling and dose timing education |
On a small screen, swipe or scroll sideways to see the full table.
Dosing overview
For erectile dysfunction, typical starting dose is 50 mg orally as needed before sexual activity, with range 25 to 100 mg based on response and tolerability, maximum once daily. For pulmonary arterial hypertension, adult dose is 20 mg orally three times daily, separated by 4 to 6 hours. Pediatric PAH dosing (ages 1–17 years) is weight-based per Revatio labeling and must follow the exact product label and specialist order—do not use adult ED or adult PAH tablet schedules for children.
| Scenario | Nursing action | Escalation trigger |
|---|---|---|
| ED use | Verify most recent dose and avoid duplicate same-day administration | Recent nitrate use, severe hypotension, or syncope symptoms |
| PAH scheduled therapy | Administer 20 mg TID with consistent 4 to 6 hour spacing | Interaction conflict on MAR or persistent symptomatic hypotension |
| Order discrepancy | Clarify indication when dose or frequency does not match expected regimen | Any unclear order that could result in overdose or omitted PAH dose |
On a small screen, swipe or scroll sideways to see the full table.
Onset, peak, duration, and half-life
| Parameter | Typical value | Nursing relevance |
|---|---|---|
| Onset (ED effect) | About 30 to 60 minutes | Counsel realistic timing expectations and avoid redosing too soon |
| Peak plasma concentration | Roughly 1 hour fasting | Watch for early BP effects after administration |
| Half-life | About 4 hours | Interaction risk persists beyond immediate administration window |
| Metabolism | Primarily hepatic (CYP3A pathway) | Check interacting medications and hepatic impairment context |
On a small screen, swipe or scroll sideways to see the full table.
Before you give it — Safety check
Pretreatment checks
- Complete interaction-focused medication reconciliation before each administration cycle
- Obtain baseline values with standardized blood pressure measurement
- Screen for alpha-blockers and other antihypertensives—coadministration can increase symptomatic hypotension risk per labeling
- If symptoms suggest orthostatic intolerance, confirm trend with an orthostatic blood pressure check per protocol
Contraindications
- Organic nitrates in any form
- Riociguat coadministration
- Hypersensitivity to sildenafil or formulation components
Important interactions
| Drug or class | Effect | Nursing action |
|---|---|---|
| Organic nitrates | Profound additive vasodilation and hypotension risk | Treat as contraindicated and hold sildenafil pending urgent prescriber review |
| Riociguat | Dangerous BP reduction due to combined cGMP signaling | Do not coadminister; escalate for alternative therapy plan |
| Tadalafil | Overlapping PDE5 effects can increase adverse reactions if misused together | Verify intended PDE5 regimen and prevent duplicate class exposure |
| Alpha-blockers and antihypertensives | Additive vasodilation can cause dizziness, syncope, and symptomatic hypotension | Reconcile tamsulosin and other alpha-blockers; monitor BP lying and standing; hold and notify for presyncope or marked BP drop |
On a small screen, swipe or scroll sideways to see the full table.
Administration
Route: Oral tablet or oral suspension. Confirm indication, timing intent, and contraindicated co-medications before each dose.
- Verify baseline hemodynamics and recent symptoms before administration
- Use consistent documentation language for hypotension symptoms such as new dizziness
- For PAH regimens, maintain 4 to 6 hour spacing and avoid omitted or bunched doses
- For ED regimens, confirm prior same-day dose to respect once-daily maximum
| Step | Nursing detail |
|---|---|
| Before dose | Check order intent (ED versus PAH), BP trend, and contraindication profile |
| During administration | Provide hydration and positioning guidance to reduce symptomatic BP drops |
| After dose | Track symptom response and hemodynamic tolerance, then document thoroughly |
| Escalation point | Hold and escalate immediately for nitrate exposure, riociguat exposure, syncope, or severe hypotension |
On a small screen, swipe or scroll sideways to see the full table.
Expected therapeutic response
- ED indication: improved erectile response with appropriate sexual stimulation
- PAH indication: better exertional tolerance and less cardiopulmonary symptom burden
- No progressive orthostatic symptoms, collapse, or hypoperfusion findings after dosing
Red flags — Stop and act
Escalate quickly if hypotension or ischemic instability appears while interaction risk is possible.
- Confirmed or suspected nitrate exposure with active sildenafil order
- Sudden presyncope or witnessed fainting after a recent dose
- Visual symptoms concerning for acute loss of vision
- New auditory change suggestive of sudden hearing loss
Adverse effects
DailyMed labeling reports vasodilatory effects such as headache, flushing, dyspepsia, and congestion, with hypotension risk amplified when contraindicated co-therapies are present.
| Adverse effect | Clinical relevance | Nursing response |
|---|---|---|
| Headache | Common vasodilatory reaction | Assess severity and reassure while maintaining interaction vigilance |
| Flushing and nasal congestion | Frequent mild effects | Differentiate tolerable effects from hemodynamic compromise |
| Hypotension | High-stakes adverse event when interactions occur | Hold dose, reposition patient, reassess BP, and escalate urgently |
| Visual or hearing disturbance | Rare but serious warning findings | Stop medication and notify prescriber immediately |
On a small screen, swipe or scroll sideways to see the full table.
Overdose, toxicity, and antidote
Sildenafil overdose can produce marked vasodilation and symptomatic hypotension. There is no specific antidote; care is supportive with rapid hemodynamic stabilization and escalation per facility protocol.
Management priorities
- Stop sildenafil and evaluate airway, circulation, and perfusion
- Position supine when hypotension is present and initiate supportive fluids if indicated
- Review full medication list for interacting agents and duplicate PDE5 exposure
- Escalate promptly for persistent hemodynamic instability or neurologic decline
| Overdose finding | Nursing and team response |
|---|---|
| Severe hypotension | Immediate hemodynamic support, frequent BP checks, and urgent clinician notification |
| Syncope or collapse | Safety protection, escalation to monitored care, and continuous reassessment |
| Worsening visual or auditory symptoms | Hold further doses and urgent prescriber assessment |
| Medication-use confusion | Clarify indication and dosing history before restarting therapy |
On a small screen, swipe or scroll sideways to see the full table.
Look-alike / sound-alike and error prevention
- Sildenafil ED versus PAH regimens must not be interchanged without indication clarification
- PRN ED timing and scheduled PAH dosing require separate MAR logic
- Interaction screen must include nitrate formulations in all routes and riociguat
- Hand-off communication should explicitly state whether dose was given, held, or clarified
Practical bedside notes
| Topic | Bedside guidance |
|---|---|
| Interaction screening | Ask specifically about nitrate spray, tablets, patches, ointment, and infusion exposure |
| PAH workflow | Schedule doses 4 to 6 hours apart and align with routine assessments |
| ED safety counseling | Reinforce once-daily maximum and no concurrent nitrate use |
| Documentation focus | Capture indication, dose timing, BP response, and any held-dose rationale |
| When to call pharmacy | Unclear indication, suspected duplicate PDE5 use, or interaction uncertainty |
On a small screen, swipe or scroll sideways to see the full table.
High-risk populations
| Population | Considerations |
|---|---|
| Patients with cardiovascular instability | Higher risk of symptomatic hypotension during interacting therapy exposure |
| Patients with concurrent antianginal therapy | Need strict contraindication checks for nitrate products |
| Hepatic or severe renal dysfunction | May have altered exposure and greater adverse-effect burden |
| Older adults | Can have amplified orthostatic symptoms and fall risk |
| Pregnancy and lactation contexts | Use indication-specific specialist and evidence review; LactMed supports breastfeeding risk review |
| Severe cardiovascular disease | Require individualized risk-benefit review before ED-focused use |
On a small screen, swipe or scroll sideways to see the full table.
Monitoring and documentation
Monitor
- Blood pressure trend and symptom correlation before and after dosing
- Any new signs of interaction toxicity, syncope risk, or perfusion decline
- Indication-specific response: ED effectiveness or PAH functional trajectory
Document
- Dose, timing, and indication for each administration
- Interaction screen findings and whether contraindicated agents were present
- Held-dose reason, escalation actions, and clinician notifications
Patient teaching
- Never combine sildenafil with nitrate products or riociguat
- For ED dosing, do not exceed once-daily use and follow prescribed strength
- For PAH dosing, keep doses spaced 4 to 6 hours apart each day
- Report sudden visual changes, hearing changes, severe dizziness, or collapse symptoms right away
- Bring all medications to each visit so interaction screening remains accurate
The Hold Rule
Do not give and contact the prescriber or pharmacist when:
- Any organic nitrate exposure is current or recent
- Riociguat appears on MAR or home medication list
- Hypersensitivity history to sildenafil is reported
- Symptomatic hypotension or collapse symptoms are present before dosing
- Indication and ordered frequency are mismatched or unclear
Align hold decisions with prescribing information, institutional policy, and pharmacist review before restarting therapy.
Clinical practice integration and workflow
Sildenafil safety depends on a reliable pre-dose interaction workflow. The one danger to prioritize on shift is missed nitrate or riociguat exposure, because that error can rapidly convert a routine dose into life-threatening hypotension.
1. Check-before-you-give protocol
- Confirm indication (ED versus PAH) and dose schedule match
- Run focused interaction check for nitrates and riociguat every time
- Capture baseline blood pressure and symptom status before administration
2. High-alert and safety badge
High-alert interaction risk medication: contraindicated with nitrates and riociguatA completed interaction screen is as essential as the dose calculation.
3. Clinical workflow: hold and question rules
- Hold immediately if nitrate or riociguat exposure is identified
- Escalate symptomatic hypotension without waiting for routine rounds
- Use closed-loop communication to document hold rationale and next plan
4. Critical teach-back questions
- “What medicines must you avoid with sildenafil?” (Any nitrate form and riociguat.)
- “How often can you use your ED dose?” (No more than once daily unless prescriber changes regimen.)
5. Care coordination
Pharmacist: Interaction verification, dose clarification, and regimen counseling
Prescriber or specialty team: Alternative plans when contraindications or instability prevent safe sildenafil use
🧠 Quick mental checklist
- Did I confirm the indication before accepting this dose schedule?
- Any nitrate or riociguat exposure that makes this dose unsafe?
- Is baseline BP acceptable for administration right now?
- Did I document action and escalation if the dose was held?
- Does the patient understand interaction and red-flag teaching?
Sildenafil NCLEX practice questions
Complete this NCLEX-style clinical judgment practice set by using case tabs (MAR, labs, vitals, and nursing notes) to identify contraindicated nitrate exposure, prioritize hypotension prevention, and apply matrix urgency decisions.
Select a tab to view MAR, labs, vitals, and nursing note details for this case.
- 55-year-old patient with pulmonary arterial hypertension
- Sildenafil 20 mg PO three times daily (06:00, 12:00, 18:00)
- Nitroglycerin patch 0.2 mg/hr appears as active home medication entry
- 07:00 sildenafil dose has not yet been administered due to order clarification
- Creatinine 1.0 mg/dL, eGFR 82 mL/min/1.73m²
- AST 30 U/L, ALT 28 U/L
- Lactate normal; no acute shock marker elevation
- 06:45 BP 112/70, HR 84, RR 18, SpO2 94%
- 07:05 BP 96/58 seated with lightheadedness
- 07:10 BP 88/52 on standing attempt, HR 104
- Patient reports “I used nitrate patch for chest symptoms at home yesterday.”
- Team asks whether scheduled sildenafil should proceed now
- Patient feels weak when standing and requests help to bathroom
Answer key & rationale
Frequently asked questions
Why is nitrate screening mandatory before sildenafil?
Nitrates and sildenafil can cause additive cGMP-mediated vasodilation that leads to severe hypotension, syncope, and poor organ perfusion, so the combination is contraindicated.
Is riociguat also contraindicated with sildenafil?
Yes. Riociguat plus sildenafil increases hypotension risk and should not be coadministered.
What is the standard PAH sildenafil adult regimen?
20 mg by mouth three times daily, with doses spaced approximately 4 to 6 hours apart.
How should ED sildenafil dosing be limited?
Typical dose is 50 mg PRN with allowable range 25 to 100 mg based on response and tolerability, and dosing should not exceed once daily.
Which adverse symptoms need urgent escalation?
Escalate immediately for syncope, severe hypotension, sudden visual loss, sudden hearing change, or collapse symptoms.
What should nurses document each time sildenafil is given or held?
Document indication, dose and time, blood pressure response, interaction-screen result, and prescriber or pharmacist communication if the dose is withheld.
References
-
U.S. National Library of Medicine. Viagra (sildenafil citrate) tablets — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=47af30e9-a189-4721-8c8f-652256df75a1
-
U.S. National Library of Medicine. Sildenafil for pulmonary arterial hypertension — Full prescribing information. DailyMed.https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f4c26992-c9bb-e20f-e053-2a95a90afb65
-
U.S. National Library of Medicine. Sildenafil. Drugs and Lactation Database (LactMed).https://www.ncbi.nlm.nih.gov/books/NBK1055/
-
NICE BNF. Sildenafil. British National Formulary.https://bnf.nice.org.uk/drugs/sildenafil/
Review and transparency
This medication guide is written and reviewed using NurseOnShift editorial and clinical review standards.
Educational use only. This content does not replace clinical judgment, prescriber orders, pharmacist guidance, product labeling, or institutional protocols.